Dr. Katie Murray discusses how advances in non–muscle invasive bladder cancer are shifting care toward a more collaborative, practice-wide model. She emphasizes the growing role of nurses and advanced practice providers in intravesical therapy delivery, patient education, and symptom management. As treatment expands beyond repeated TURBTs, Dr. Murray highlights the need for the entire care team to understand evolving protocols and toxicities.
2026 Advances and Ongoing Challenges in HR-positive, HER2-Negative Metastatic Breast Cancer
Recent advances have reshaped the management of HR-positive, HER2-negative metastatic breast cancer, with CDK4/6 inhibitors, genomically driven targeted therapies, and antibody–drug conjugates expanding treatment durability beyond endocrine therapy alone. This review synthesizes emerging clinical trial data, mechanisms of resistance, and evolving sequencing strategies that will influence precision-based care and real-world decision-making in 2026.
